Get the Stockscreener App
3.96
4.21%
0.16
After Hours:
3.90
-0.06
-1.52%
Rocket Pharmaceuticals Inc stock is traded at $3.96, with a volume of 2.58M.
It is up +4.21% in the last 24 hours and up +16.81% over the past month.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.
See More
Previous Close:
$3.80
Open:
$3.8
24h Volume:
2.58M
Relative Volume:
1.14
Market Cap:
$428.56M
Revenue:
-
Net Income/Loss:
$-258.08M
P/E Ratio:
-1.44
EPS:
-2.75
Net Cash Flow:
$-202.32M
1W Performance:
+1.80%
1M Performance:
+16.81%
6M Performance:
+29.84%
1Y Performance:
-62.03%
1-Day Range:
$3.7914
$3.98
1-Week Range:
$3.47
$4.00
52-Week Range:
$2.19
$11.45
Rocket Pharmaceuticals Inc Stock (RCKT) Company Profile
Name
Rocket Pharmaceuticals Inc
Sector
Industry
Phone
646-440-9100
Address
350 FIFTH AVENUE, NEW YORK, NY
Compare RCKT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RCKT
Rocket Pharmaceuticals Inc
|
3.96 | 411.24M | 0 | -258.08M | -202.32M | -2.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
449.53 | 115.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.14 | 79.76B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
799.33 | 50.16B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
366.86 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.75 | 38.85B | 4.98B | 69.59M | 525.67M | 0.5197 |
Rocket Pharmaceuticals Inc Stock (RCKT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-18-25 | Downgrade | JP Morgan | Neutral → Underweight |
| Aug-20-25 | Upgrade | BofA Securities | Neutral → Buy |
| Jul-25-25 | Downgrade | BofA Securities | Buy → Neutral |
| May-30-25 | Downgrade | Evercore ISI | Outperform → In-line |
| May-28-25 | Downgrade | Goldman | Neutral → Sell |
| May-28-25 | Downgrade | JP Morgan | Overweight → Neutral |
| May-28-25 | Downgrade | Jefferies | Buy → Hold |
| May-28-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| May-28-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| May-27-25 | Downgrade | Needham | Buy → Hold |
| May-27-25 | Downgrade | TD Cowen | Buy → Hold |
| Mar-12-25 | Initiated | BMO Capital Markets | Outperform |
| Dec-30-24 | Initiated | Wedbush | Outperform |
| Dec-18-24 | Initiated | Jefferies | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Apr-02-24 | Initiated | Goldman | Neutral |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-01-23 | Initiated | Morgan Stanley | Overweight |
| Nov-08-22 | Initiated | Canaccord Genuity | Buy |
| Nov-01-22 | Initiated | BTIG Research | Buy |
| Jul-08-22 | Initiated | Raymond James | Outperform |
| Oct-20-21 | Resumed | Cowen | Outperform |
| Mar-02-21 | Initiated | Stifel | Buy |
| Feb-18-21 | Initiated | Needham | Buy |
| Dec-16-20 | Initiated | UBS | Buy |
| Dec-08-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-02-20 | Initiated | JP Morgan | Overweight |
| Jun-25-20 | Resumed | BofA/Merrill | Buy |
| Jun-01-20 | Resumed | Oppenheimer | Outperform |
| Nov-06-19 | Initiated | Chardan Capital Markets | Buy |
| Sep-26-19 | Initiated | Piper Jaffray | Overweight |
| Apr-23-19 | Initiated | Robert W. Baird | Outperform |
| Mar-15-19 | Initiated | BofA/Merrill | Buy |
| Feb-05-19 | Initiated | Oppenheimer | Outperform |
| Sep-13-18 | Initiated | Ladenburg Thalmann | Buy |
| Jul-10-18 | Initiated | William Blair | Outperform |
View All
Rocket Pharmaceuticals Inc Stock (RCKT) Latest News
RCKT: 2026 will see key clinical milestones and a potential first commercial launch in gene therapy - TradingView — Track All Markets
Will Rocket Pharmaceuticals Inc benefit from sector rotationJuly 2025 Volume & Technical Pattern Alert System - baoquankhu1.vn
Value Recap: What Wall Street predicts for Rocket Pharmaceuticals Inc stock priceMarket Performance Report & Daily Stock Trend Watchlist - Bộ Nội Vụ
Aug Summary: Why Rocket Pharmaceuticals Inc Equity Warrant stock remains undervaluedM&A Rumor & AI Enhanced Trade Execution Alerts - Bộ Nội Vụ
Fundamentals Check: How buybacks impact Rocket Pharmaceuticals Inc. stock value2025 Pullback Review & Reliable Trade Execution Plans - Bộ Nội Vụ
Earnings Beat: Can Rocket Pharmaceuticals Inc expand into new markets2025 Analyst Calls & Risk Managed Investment Entry Signals - baoquankhu1.vn
How Rocket Pharmaceuticals Inc. Equity Warrant stock performs in weak economyMarket Sentiment Report & AI Powered Buy/Sell Recommendations - Улправда
Published on: 2026-01-10 12:46:55 - Улправда
Rocket Pharmaceuticals, Inc.Common Stock (NQ: RCKT - FinancialContent
Rocket Pharmaceuticals, Inc. (RCKT) Stock Analysis: Exploring a 100% Upside Potential in the Biotech Sector - DirectorsTalk Interviews
Will Rocket Pharmaceuticals Inc. Equity Warrant stock rally after Fed decisionsJuly 2025 Movers & Precise Entry and Exit Recommendations - ulpravda.ru
Cash per share of Rocket Pharmaceuticals, Inc. Warrant 2023- on Rocket Pharmctc – NASDAQ:RCKTW - TradingView — Track All Markets
Why Rocket Pharmaceuticals Inc. stock could outperform in 2025Take Profit & Short-Term Swing Trade Alerts - Улправда
How rising interest rates impact Rocket Pharmaceuticals Inc. stockJuly 2025 Drop Watch & Smart Allocation Stock Tips - Улправда
Can Rocket Pharmaceuticals Inc. Equity Warrant stock resist sector downturns2025 Historical Comparison & Free AI Powered Buy and Sell Recommendations - ulpravda.ru
What is the fair value of Rocket Pharmaceuticals Inc. stock nowEquity Performance Review & High Return Portfolio Growth - Улправда
Will Rocket Pharmaceuticals Inc. Equity Warrant stock continue upward momentumFootwear buying guidance for daily running and walking routines focuses on breathable comfort for long hours, making it a reliable option for purchase decisions. - ulpravda.ru
Rocket Pharmaceuticals to Participate in the 44th Annual J.P. Morgan Healthcare Conference - BioSpace
What analysts say about Rocket Pharmaceuticals Inc stockPortfolio Risk Assessment & Double Or Triple Capital - earlytimes.in
The Truth About Rocket Pharmaceuticals: Is RCKT About To Explode Or Crash? - AD HOC NEWS
Rocket Pharmaceuticals (NASDAQ:RCKT) Shares Cross Below 50 Day Moving AverageShould You Sell? - MarketBeat
Can Rocket Pharmaceuticals Inc. Equity Warrant stock maintain growth trajectoryHigh Yield Income Stocks & Connect With Bulls, Avoid the Bears - bollywoodhelpline.com
Rocket Pharmaceuticals: Upside On LAD-I Approval And Amended Danon Program - Seeking Alpha
Is Rocket Pharmaceuticals (RCKT) One of the Best NASDAQ Stocks Under $5 to Buy Now? - MSN
Published on: 2025-12-24 06:58:20 - earlytimes.in
Will Rocket Pharmaceuticals Inc. Equity Warrant stock remain a Wall Street favoriteWeekly Profit Analysis & Long Hold Capital Preservation Plans - Улправда
How buybacks impact Rocket Pharmaceuticals Inc. stock valueMarket Rally & Expert Approved Momentum Trade Ideas - Улправда
Will Rocket Pharmaceuticals Inc. Equity Warrant stock outperform Nasdaq indexJuly 2025 Weekly Recap & Daily Entry Point Alerts - Bölüm Sonu Canavarı
Published on: 2025-12-20 17:40:18 - Улправда
Rocket Pharmaceuticals (NASDAQ:RCKT) Raised to Hold at TD Cowen - MarketBeat
Published on: 2025-12-20 11:21:01 - Улправда
Is Rocket Pharmaceuticals Inc. Equity Warrant stock dividend yield sustainableJuly 2025 Snapshot & Real-Time Chart Breakout Alerts - Улправда
Can Rocket Pharmaceuticals Inc. Equity Warrant stock sustain institutional interest2025 Breakouts & Breakdowns & Weekly Top Performers Watchlists - Улправда
Can Rocket Pharmaceuticals Inc. stock hit analyst price targetsMarket Risk Report & Daily Entry Point Alerts - Улправда
What margin trends mean for Rocket Pharmaceuticals Inc. Equity Warrant stockJuly 2025 Pullbacks & Real-Time Volume Spike Alerts - Улправда
Published on: 2025-12-19 17:54:30 - DonanımHaber
Will Rocket Pharmaceuticals Inc. stock rally after Fed decisions2025 Retail Activity & Long-Term Growth Portfolio Plans - DonanımHaber
Will Rocket Pharmaceuticals Inc. Equity Warrant stock maintain dividend yieldJuly 2025 Levels & Safe Swing Trade Setups - DonanımHaber
Stop Loss: Will Rocket Pharmaceuticals Inc. Equity Warrant stock rally after Fed decisionsWeekly Risk Report & Verified Short-Term Trading Plans - DonanımHaber
Analysts Have Conflicting Sentiments on These Healthcare Companies: Insmed (INSM), Novan (NOVN) and Rocket Pharmaceuticals (RCKT) - The Globe and Mail
Rally Mode: What is the fair value of Rocket Pharmaceuticals Inc. stock nowJuly 2025 WrapUp & Low Drawdown Trading Techniques - ulpravda.ru
Why analysts remain bullish on Rocket Pharmaceuticals Inc. stockWeekly Trade Report & High Accuracy Trade Alerts - Улправда
Published on: 2025-12-18 16:59:15 - Улправда
Market Fear: Will Rocket Pharmaceuticals Inc. Equity Warrant stock continue upward momentum2025 Market Overview & Intraday High Probability Alerts - Улправда
Published on: 2025-12-18 16:13:14 - Улправда
Rocket Pharmaceuticals Leads Our Trio Of Penny Stock Contenders - Yahoo Finance
Rocket Pharmaceuticals Inc Stock (RCKT) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.44%
0.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):